Gilead presented data on the safety of its long-acting ARV drug
Last Thursday, March 7, on the closing day of the International Conference on Retroviruses and Opportunistic Infections (CROI2019), the first data on the safety and tolerability of a fundamentally new ART-medication of prolonged action GS-6207 were presented. The development of the pharmaceutical company Gilead Sciences is a selective multistage capsid inhibitor HIV molecule.
9 三月 2019 15:35
Mortality from breast cancer is more common among women with HIV
According to a cohort study presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019) in Seattle, the mortality rate among HIV-positive women with breast cancer (BC) is higher than among those with a negative status.
更多
8 三月 2019 15:53
Test and Treat Principle Reduces the Number of New HIV Cases in South Africa by 30%
According to the latest data presented at the Conference on Retroviruses and Opportunistic Infections (CROI2019), the number of new HIV infections in southern Africa can be significantly reduced by voluntary testing for HIV in communities and immediately ...
更多
U=U运动 (#UequalsU)
我的生活+在东欧和中亚地区组织的信息和教育活动 "U=U" （“无法检测到等于不可传播”，#UnqualsU，#НравноН）旨在传达一个信息，即HIV阳性者在病毒载量无法被检测到时，不能将病毒通过性行为传染给另一个人。
许多研究表明，在血清不一致的夫妇中，HIV阳性伴侣接受ARV治疗并保持无法检测到的病毒载量，则没有HIV性传播病例的发生。
我们的合作伙伴
